Faculty & Staff
Contact
-
Email
rikgangulybioinfo@gmail.com
- Websites
Dr. Rik Ganguly
Assistant Professor
-
School/College
Faculty of Life and Allied Health Sciences
-
Department
Department of Biotechnology
Dr. Rik Ganguly completed his B.Sc. in Microbiology and M.Sc. in Molecular Microbiology, followed by a Ph.D. in Biotechnology from North-Eastern Hill University (NEHU), Shillong. During his academic and research career, he has gained expertise in computational biology, structural bioinformatics, molecular modelling, AI/ML-based drug discovery, peptide engineering and molecular dynamics simulations. He has worked in both academic and industrial research environments, including Cellogen Therapeutics, Ashoka University and the Indian Institute of Technology Roorkee. His research interests broadly encompass computational drug discovery, structure-based drug design, antimicrobial resistance, AI-driven biomolecular engineering and the development of physics-informed computational approaches for therapeutic discovery.
Qualifications
- PhD
Biotechnology and Bioinformatics 2026
- PG Programme
M.Sc. Molecular Microbiology , University of Hyderabad 2015
- UG Programme
B.Sc. Microbiology, University of Kalyani 2013
Experience
Total Years of Experience2.41 Years
Academic Experience
- 2 years of academic/research experience
- 7 years including PhD
Industry Experience
- Cellogen Therapeutics - 11 months
- Computational Biophysics; Structural Biology; Geometric Deep Learning for Molecular Systems; Molecular Dynamics Simulations; AI/ML-Driven Drug Discovery; Structure-Based Drug Design; Protein and Peptide Engineering; Cyclic Peptide Design; Nanobody Engineering; Molecular Glues; PROTACs and Targeted Protein Degradation; Antimicrobial Resistance; β-Lactamase Inhibitor Discovery; Vaccine Design; and Therapeutic Molecular Engineering.
- Ganguly R, et al. (2024). ‘Herbal Medicine: History, Contemporary Use and the Future’. In: Herbs for Disease Prevention and Treatment. Bentham Science Publishers, pp. 148–173.
- National Eligibility Test (NET), Agricultural Microbiology - ASRB, ICAR, 2017.
- First class second in Bsc from Kalyani university.
- Best Poster Presentation Award, InBix 2021, for the presentation “Enrichment of pharmacokinetic characteristics of UK122, a potential inhibitor of uPA”, March 2021.
- Co-author, First DREAM Target 2035 DEL–ML Challenge Overview Manuscript, a global drug discovery challenge organized through the Structural Genomics Consortium, University of Toronto — contributed computational methodology to an international benchmarking study on DNA-encoded library prediction models.
National Conference Papers
- Ganguly R. ‘Enrichment-based optimization of in silico inhibitor screening parameters for ADAMTS-4’. National Conference: Current Trends in Medical Biotechnology, November 2022.
- Ganguly R. ‘Identification of repurposed FDA-approved drugs against SARS-CoV-2 Omicron’. Contemporary Research in Biotechnology, NEHU, March 2022.
- Ganguly R. ‘Repurposing FDA-approved drugs targeting RBD of SARS-CoV-2 Omicron spike protein’. Integrated Approach to Science & Technology for a Sustainable Future, October 2022.
- Ganguly R. ‘Enrichment of pharmacokinetic characteristics of UK122, a potential inhibitor of uPA’. InBix 2021, March 2021. Best Poster Presentation Award.
International Conference Papers
- Ahuja G, et al., Ganguly R, et al. ‘PRISM: Physician Rules Integrated with Small Large Language Models for Probable Diagnoses Associated with Abdominal Pain’. NeurIPS 2025 – Second Workshop on GenAI for Health.
- Ganguly R, Roy R, Bhattacharjee A. ‘Selecting optimal molecular interaction settings through enrichment analysis and data mining’. ICCMSE 2023, Gandhinagar, India. Springer Nature.
National Journal Papers
- Ganguly R, Yadav SK, Bhattacharjee A. ‘Topotecan and (22S)-Budesonide as potential drug candidates against ORF3a’. NEHU Journal.
- Ganguly R, Bhattacharjee A. ‘Atherosclerotic plaque development: Disease pathogenesis and emerging treatment options’. NEHU Journal, 2019.
International Journal Papers
- Ganguly R, Mylliemngap BJ, Bhattacharjee A. ‘Discovery of a novel inhibitor against urokinase-type plasminogen activator’. Journal of Biomolecular Structure and Dynamics. 2023; 41(8): 3485–3495.
- Akhtar A, et al., Ganguly R, et al. ‘Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term antitumor activity’. Cell Reports Medicine. 6(3).
- Das S, Bagchi A, Bera A, et al., Ganguly R, et al. ‘In silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase’. Scientific Reports. 15(1): 23626.
- Jamir K, Ganguly R, Seshagirirao KC. ‘ZCPG, a cysteine protease from Zingiber montanum rhizome exhibits enhanced anti-inflammatory and acetylcholinesterase inhibition potential’. International Journal of Biological Macromolecules. 2020; 163: 2429–2438.
- Ngoruh A, Anand AA, Ganguly R, Yadav SK, Ingty P, Samanta SK, et al. ‘Identification of receptor-interacting protein kinase 3 inhibitor for atherosclerosis’. Journal of Receptors and Signal Transduction. 2026: 1–16.
- Ganguly R, et al. ‘Identification of an inhibitor for the atherosclerotic enzyme NOX-1 to inhibit ROS production’. Future Journal of Pharmaceutical Sciences.
- Ganguly R, et al. ‘Designing a multi-epitope vaccine against SARS-CoV-2’. International Journal of Pharmaceutical Sciences and Drug Research.
- Yadav SK, Ganguly R, Bhattacharjee A. ‘Discovery of repurposed FDA-approved drugs against SARS-CoV-2 Omicron’. Journal of Advanced Scientific Research.
- Dharavath S, et al., Ganguly R, et al. (2022). ‘Artificial Intelligence to Identify Heart Valve Blocks and Targeted Nanoparticle Delivery’. Indian Patent No. 202241018235 (Published).
ADDRESS
